Skip to content
Menu

Lexicon Pharmaceuticals, Inc. LXRX

Full chart Compare
Set alert

Price alert · LXRX

All alert types
1.75 USD -0.04 (-2.23%)

Regular-session close

1.74 -0.01 -0.57%

After hours · Nov 16, 5:58 PM ET

1.73 Day range 1.84
1.14 52-week range 2.64
YTD
+52.17%
1 year
+17.45%

Discussion (470)

Goinglong LXRX 9 months ago #11

Still very likely a partnership could be announced soon, still weeks from their next earnings call as well as key pain conferences, both of which would be ideal times to drop the news.

Goinglong LXRX 9 months ago #12

Any chance the partnership deal is gonna be announced by their earnings call

Goinglong LXRX 9 months ago #13

Dang, are we going to break $1.50 before tomorrows close?

Goinglong LXRX 9 months ago #14

No news at this point tells me they are still negotiating, time is of the essence and they have known the FDA direction since Q4 2025.

I can’t see going at it alone as an option really, for what ? Most likely to expect same results as phase 2? Then what? HUGE risk.

Need to package this up before next earning call

Goinglong LXRX 9 months ago #15

I sold all my Lexicon stock and bought $2 Feb and March calls. After following the stock for several years, and understanding it from the perspective of a spouse of a sales rep selling Impefa, I really hope that they don’t try to go at it alone with LX9211. I also can’t understand any reasonable reason why after a successful Q4 FDA meeting they wouldn’t be able to secure a partnership if one was coming by their March earning call, presumably 90 days later.

Moving LX9211 into Phase 3 alone is a "binary" bet-the-company risk because Lexicon is essentially trading its remaining $100M+ cash war chest for a single roll of the clinical dice. While the FDA clearance of the 10mg doseprovides a roadmap, self-funding a pivotal trial without the "Big Pharma" safety net means any delay in enrollment or mixed data readout could leave them insolvent by 2027. They are operating in the shadow of Vertex's head start, with better data readouts, meaning they have zero margin for error; if the trial fails, Lexicon loses its most valuable pipeline asset and the financial means to support its other initiatives, likely forcing a "fire sale" of the company

Goinglong LXRX 9 months ago #16

I am really hoping for some type of partnership deal by their March earnings call

Lexicon is entering a high-stakes "all-in" phase. By launching Phase 3 alone, they are trading financial security for the chance at a massive valuation spike.

The Risks of Going Solo

Financial Exhaustion: Phase 3 costs are massive. Lexicon is betting nearly their entire cash runway on a single outcome; any delay in recruitment or cost overruns could leave them insolvent before results are in

The "Vertex Gap": Vertex’s head start is a major threat. If Vertex captures the market early and locks in physician loyalty, Lexicon's drug becomes a "me-too" product with a smaller commercial upside.

Operational Strain: Unlike Big Pharma, Lexicon lacks a global clinical infrastructure, making them more vulnerable to trial execution errors.
Milestones Needed for Leverage
SPA Agreement: Securing an FDA Special Protocol Assessment would prove the trial's design is sufficient for approval, significantly de-risking the asset for a partner.
Enrollment Velocity: Meeting recruitment targets on time would prove there is still patient/physician interest despite Vertex’s lead.
The "Vertex Stumble": Any safety or efficacy issues in Vertex’s Phase 3 data would immediately make Lexicon the most valuable "Plan B" in the industry.
The Failure Scenario
Pipeline Collapse: If the 10 mg dose fails, LX9211 is likely dead. Lexicon would have spent its $100M+ war chest on a failed asset.
Financial Shell: They would be left with a cratered stock price and minimal cash, likely forcing a pivot to a "skeleton crew" operation supported only by modest royalties and INPEFA sales.
Takeover Target: At that point, Lexicon would likely be sold for parts or acquired for its remaining Intellectual Property at a steep discount.
The Bottom Line: Lexicon is attempting to prove the drug's worth by doing the "heavy lifting" themselves. If they show a clean start to Phase 3, a partner will likely step in to pay for the finish line. If they can't find a partner by mid-2026, the financial pressure will become critical

Goinglong LXRX 9 months ago #17

I sold all my shares and bought Feb and March $2 calls, IMO if there are no significant partnerships developments by their next earnings call they are toast. Sure they raised enough money to start a phase 3 trail for LX9211, but their top competitor for this drug is much farther along and It has much cleaner data and efficacy.

House owning this stock seems incredibly risky at this point, even more so than any time in the past few years.

Even with a deal, if it’s still coming, may not be front loaded enough to really move their share price much. My hopes is that whatever deal might be announced will create a short squeeze to make a two dollar calls worthwhile, briefly anyway.

Goinglong LXRX 9 months ago #18

Is there are no significant partnerships, deals or a buyout by March earnings call I think they are dead in the water. I’m hopeful for a partnership on LX9211, but I’m beginning to doubt that there’s gonna be much Front loaded cash and it would be much more back loaded. If they go out alone, they’re basically burning the ship behind them, and we’re just gonna continue to see more and more dilution.

I have been long for several year, my spouse worked for this company during Impefa launch. I have long believed LX9211 was one of their major assets, and very disappointed to have not seen a partnership announced along with the January announcement of the successful FDA meeting.
There’s really not a lot of meat on the bone anymore,

Goinglong LXRX 9 months ago #19

During the February 5, 2026 BMS earnings call, CEO Chris Boerner provided several coded but potent signals that align with a potential LX9211 partnership. Most notably, he elevated Neuroscience to a "core growth pillar" for BMS and specifically emphasized a strategy of pursuing "bolt-on" acquisitions to build out the franchise surrounding their new drug, Cobenfy. By defining "bolt-on" assets as those that leverage their existing sales force and target the same physician base, he described the exact commercial profile of a neuropathic pain drug like LX9211, which BMS originally co-developed.
Furthermore, Boerner’s repeated use of the word "disciplined" regarding business development served as a strategic "price guardrail." This verbiage allows BMS to frame any upcoming deal as a calculated, high-value move rather than a desperate one, effectively "covering" the executive team's reputation just before a potential announcement. By establishing the strategic "why" during the earnings call, he cleared the runway for a "clean" partnership announcement in the following days, ensuring the market views such a move as a deliberate execution of the vision he just laid out

Goinglong LXRX 9 months ago #20

BMS earnings were today plus the stock market took a beating

Sign in to join the discussion